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Abstract 
Objective: To find out the changes in lipid metabolism among patients suffering 
from chronic liver disease secondary to hepatitis C. Study Design: Hospital based 
observational study. Setting: Medical Unit-I, Ward–5, Jinnah Postgraduate Medical 
Centre, Karachi. Duration: July 2013 to December 2013. Patients and Methods: 
About 110 patients admitted in Medical Unit-I with a diagnosis of chronic liver dis-
ease were included in the study. Patients suffering from DM, HTN, CKD were ex-
cluded from the study. Fasting lipid profile was done in all cases. Results and Ob-
servations: There were 44 (40%) male and 66 (60%) female patients. Mean age of the 
patients was 50.18 (±11.7) years. Total cholesterol was decreased in 76 (69.09%) pa-
tients. Normal range was present in 34 (30.91%) patients. None of the patient had 
hypercholesterolemia. Serum triglyceride levels were low in 14 (12.72%) patients, 
normal in 82 (74.54%), borderline high in 7 (6.36%) and hypertriglyceridemia was 
seen in 7 (6.36%). HDL-c was below normal in 26 (23.63%) cases, normal in 78 
(70.91%), and high in 6 (5.45%). LDL was near optimal/above optimal in only 5 
(4.5%) patients. Mean TC/HDL ratio was 2.53 (±1.02). Mean LDL/HDL ratio was 
1.23 (±0.73). Mean TC of HCV +ve patients was 130.5 mg/dl as compared to that of 
HCV –ve patients which was 82.85 mg/dl (P-value: 0.011). Mean TGs of HCV +ve 
group was 151.5 mg/dl while that of HCV –ve was 79.9 mg/dl (P-value: 0.025). Mean 
HDL & LDL levels were 43.67 mg/dl and 39.78 mg/dl in HCV group while 34.83 
mg/dl & 64.67 mg/dl in the other group with P-value of 0.026 and 0.081 respectively. 
Conclusion: When it comes to its relationship with lipid metabolism, HCV is a re-
markable virus. Its interaction with lipoproteins and its ability to induce massive 
steatosis are quite unique and idiosyncratic. Despite of causing hepatic steatosis, 
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chronic HCV infection is associated with a paradoxically favorable lipid profile, al-
though its reason cannot be enlightened precisely. There is a need for very well set-
tled molecular and genetic studies to well understand HCV infection and lipid me-
tabolism. 
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1. Introduction 
Hepatitis C is a worldwide problem. The hepatitis C virus is a major cause of both acute 
and chronic hepatitis. An estimated population of more than 185 million worldwide 
was infected with hepatitis C virus in 2005, making a prevalence of 2.8% [1] [2]. Hepa-
titis C is divided into six distinct genotypes throughout the world with multiple sub-
types in each genotype class. Among them, genotypes 1, 2, and 3 appear to have a 
worldwide distribution and their relative prevalence varies from one geographic area to 
another. HCV subtypes 1a and 1b are the most common genotypes in the United States 
[3]. These subtypes also are predominant in Europe. The predominant HCV genotype 
in Pakistan is type 3a followed by 3b and 1a [4]. 
Many authors had made efforts to find out the interaction between chronic hepatitis 
C virus and lipid metabolism [5] [6]. Several important interactions were noticed. First, 
host serum lipid has a role in the entry of hepatitis C virion in liver cells and its circula-
tion in blood. A fraction of circulating hepatitis C viral particles makes lipoviroparticles 
on assimilation with host lipoproteins [7], and uses LDL receptors to get entered in he-
patocytes [8]. After entering into the hepatocytes, the replication of HCV virion is again 
dependent on host lipid interactions. New hepatitis C virion formation requires viral 
binding to either an endoplasmic reticulum phospholipid membrane or an endoplas-
mic reticulum-associated membranous web [9]. 
HCV reproduction may produce effects similar to those observed with HMGR inhi-
bitors. Intrahepatic cholesterol synthesis is affected by HCV through two possible path- 
ways; first, it may shunt geranylpyrophosphate, out of the mevalonate pathway, de-
creasing the quantity of this necessary intermediate available for cholesterol synthesis. 
Second, it may divert cholesterol to the synthesis of intracellular membranes that are 
necessary for the viral replication complex. The net effect of these diversions is the de-
crease of available cholesterol for physiologic intracellular processes and for peripheral 
delivery via VLDL, ultimately resulting in decreased serum cholesterol levels. The de-
crease in available intracellular cholesterol may also lead to an increase in LDL recep-
tors and intrahepatic LDL. This increase in LDL uptake may account for the decreased 
serum LDL levels in HCV infection [9]. Also the metabolic processes which are asso-
ciated with viral replication may be associated with a drop in triglycerides levels [10] 
[11]. 
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2. Materials and Methods 
This study was carried out in the Department of Medicine, Medical Unit-I, Ward-5, 
Jinnah Postgraduate Medical Centre, which is a tertiary care public sector hospital in 
Karachi, Pakistan with four medical units where around 4000 patients are admitted 
annually in each unit. About 110 patients were consecutively enrolled from July 2013 to 
December 2013. The patients included were suffering from chronic liver disease. Most 
of the patients belong to class B and C of Child Pugh’s Classification. Table 1 refers the 
child Pugh’s classification. Study was approved by research ethics committee (REC) of 
the institute and all patients gave informed written consent. 
2.1. Exclusion Criteria 
1. Patients with hepatitis B infection or any other chronic liver disease.. 
2. Patients consuming alcohol or on lipid lowering medications. 
3. The body mass index of >30 kg/m2. 
4. The patients suffering from concomitant illnesses like diabetes mellitus, hyperten-
sion, chronic kidney disease or thyroid problem. 
All patients in this study were subjected to: 
1. Full medical history and examination. 
2. Liver function tests (total plasma proteins, serum albumins, SGOT, SGPT, total 
and direct serum bilirubin, alkaline phosphatase and prothrombin time). 
3. Lipid profile: Fasting cholesterol, low density lipoproteins (LDL), high density li-
poproteins (HDL), and triglycerides. 
4. Kidney functions tests (serum urea and creatinine). 
5. Random blood glucose level and electrolytes. 
6. Complete blood count. 
7. Anti HCV antibody. 
8. Thyroid function test. 
 
Table 1. Child Pugh’s classification. 
Clinical and Lab criteria 
Points 
1 2 3 
Encephalopathy None Mild to moderate 
(Grade 1 or 2) 
Severe 
(Grade 3 or 4) 
Ascites None Mild to moderate 
(Diuretic responsive) 
Severe 
(Diuretic refractory) 
Bilirubin (mg/dl) <2 2 - 3 >3 
Albumin >3.5 2.8 - 3.5 <2.8 
Coagulation 
PT (seconds prolonged) 
Or 
INR 
<4 
 
<1.7 
4 - 6 
 
1.7 - 2.3 
>6 
 
>2.3 
Child Turcotte-Pugh class (obtained by adding score of each parameter) [12] [13]. Child A (5 - 6): Mild disease; 
Child B (7 - 9): Moderate disease; Child C (10 - 15): Severe disease. 
F. A. Q. Arisar et al. 
 
336 
9. Abdominal ultrasound. 
10. Body mass index (BMI) (weight in kilogram/height in cubic meter). 
2.2. Operational Definitions 
Levels of triglycerides and total, LDL & HDL cholestrols were defined according to ATP 
III classification as shown in Table 2. 
2.3. Data Management 
Statistical analysis was done using SPSS statistical package version 19 and results were 
got as mean ± standard deviation (mean ± SD). For statistical analysis, independent 
sample t test was used and the relation between variables was examined with Pearson 
correlation. P < 0.05 value was accepted meaningful statistically. 
3. Results 
There were 44 (40%) male and 66 (60%) female patients. Mean age of the patients was 
50.18 (±11.70) years. Most of the cases belonged to middle age group. Age and gender 
distribution of the 110 patients included in the study is shown in Figure 1 & Figure 2, 
while Figure 3 shows prevalence of HCV among study patients. Table 3 summarizes 
the laboratory parameter of patients included in study along with their child and MELD 
scores which were comparable in the two groups. 
In our group of study, total cholesterol was decreased in 76 (69.09%) patients while 
 
Table 2. ATP III classification of triglycerides and total, LDL & HDL cholestrols (mg/dl) [14] 
[15] [16]. 
 Range Interpretation 
Triglycerides 
<150 Normal 
150 - 199 Borderline high 
200 - 499 High 
>500 Very high 
Total Cholestrol 
<200 Desirable 
200 - 239 Borderline high 
>240 High 
LDL Cholestrol 
<100 Optimal 
100 - 129 Near optimal 
130 - 159 Borderline high 
160 - 189 High 
>190 Very high 
HDL Cholestrol 
<40 Low 
40 - 60 Optimal 
>60 High 
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Figure 1. Histogram showing age frequency of patients included 
in study. 
 
 
Figure 2. Gender distribution of patients included in study. 
 
 
Figure 3. Prevalence of hepatitis C among study group. 
 
normal range was present in 34 (30.91%) patients. None of the patient had hypercho-
lesterolemia. 
Serum triglyceride levels were low in 14 (12.72%) patients, normal in 82 (74.54%), 
borderline high in 7 (6.36%) and hypertriglyceridemia was seen in 7 (6.36%). HDL-c  
44
40%66
60%
Male Female
96
87%
14
13%
HCV +ve HCV -ve
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Table 3. Laboratory parameters of patients enrolled in study. 
 HCV −ve HCV +ve P-value 
Gender (Male) 14 (50%) 32 (39%) NA 
Age 40.00 (±11.40) 51.46 (±11.34) 0.057 
Hemoglobin (mg/dl) 8.88 (±2.36) 8.11 (±2.25) 0.477 
Platelets 144.67 (±90.09) 90.49 (±50.50) 0.204 
Creatinine (mg/dl) 2.08 (±1.89) 1.15 (±0.63) 0.284 
Total Bilirubin (mg/dl) 3.5 (±5.74) 3.7 (±4.13) 0.963 
Serum Albumin (mg/dl) 2.4 (±0.73) 3.67 (±4.67) 0.124 
INR 1.33 (±0.20) 1.64 (±0.64) 0.025* 
CTP score 8.6 (±1.67) 9.04 (±2.13) 0.606 
MELD 17.80 (±8.075) 16.18 (±6.725) 0.685 
NA: Not applicable; *Significant P-value. 
 
was below normal in 26 (23.63%) cases, normal in 78 (70.91%), and high in 6 (5.45%). 
LDL was near optimal/above optimal in only 5 (4.5%) patients. Mean TC/HDL ratio 
was 2.53 (±1.02). Mean LDL/HDL ratio was 1.23 (±0.73). When compared, there was 
significant difference among patients who were HCV positive vs HCV negative patients 
in terms of total cholesterol [82.85 mg/dl vs 130.5 mg/dl (p-value 0.011)], triglycerides 
[79.09 mg/dl vs 151.5 mg/dl (p-value 0.025)], HDL cholesterol [43.67 mg/dl vs 34.83 
mg/dl (p-value 0.026)], TC/HDL ratio [2.23 vs 3.89 (p-value 0.030)], however difference 
between LDL cholesterol and LDL/HDL ratio between the two groups was not signifi-
cant as shown in Figure 4. 
4. Discussion 
Dyslipidemia is a frequent finding in chronic liver disease and HCV. Internationally 
this subject has been dealt in detail. But to the best of our knowledge no study was done 
for dyslipidemia in chronic liver disease secondary to HCV in Pakistan. So it was aimed 
to contribute to the literature through this study. 
When it comes to its relationship with lipid metabolism, HCV is a remarkable virus. 
Its interaction with lipoproteins and its ability to induce massive steatosis are quite 
unique and idiosyncratic. In addition, HCV infection is generally associated with glu-
cose tolerance disorder or diabetes and both these two situations are closely related 
with steatosis. Due to these two situations, HCV infection can be related with lipid me-
tabolism indirectly. 
Although changed serum lipid is commonly found in patients with chronic liver dis-
ease of any etiology, the relationship between HCV and lipid metabolism seems to be 
more specific. 
Fernandez-Rodriguez et al. [17] documented in their study that Hepatitis C genotype 
3 chronic liver diseases is associated with serum lipid changes and these changes are  
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Figure 4. Comparison of lipids among patients with hepatitis C Vs non hepatitis C CLD. 
 
reversible with sustained viral response. This interference with lipid pathway is related 
to viral load. 
Patients in the HCV Group had significantly lower total cholesterol and LDL-c levels 
than the HCV negative control group, (P: 0.011 and 0.081 respectively). These results 
agree with Fabris et al. [5], Serfaty et al. [6], Marzouk et al. [11], Floris-Moore et al. 
[18], Corey et al. [19], Ehab H Nashaat [20], Mustafa Güçlü [21], and Mahmoud A. 
Khattab, 2012 [22], who observed that frequency of hypocholesterolemia in noncirr-
hotic HCV-infected patients was five times higher than in their reference population. 
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Also patients in the HCV group had significantly lower triglycerides levels when 
compared to the uninfected control group (p = 0.025). These results agree with Perle-
muter et al. [10], Marzouk et al. [11], Ehab H Nashaat [20], and Mahmoud A. Khattab 
[22], which refers this drop to the metabolic processes associated with viral replication. 
But these results disagree with Corey et al. [19] and Mustafa Güçlü [21], who did not 
found significant difference as regard triglycerides between patients and controls. 
HDL levels were also statistically significant between the HCV group and uninfected 
controls (p = 0.026). These results agree with Mahmoud A. Khattab et al. [22], but dis-
agree with Corey et al. [19], Ehab H. Nashaat [20], and Mustafa Güçlü et al. [21]. 
Smaller sample size and unequal number of patients in the two groups due to con-
secutive sampling seems to be potential limitation of our study which actually reflects 
the commonest cause of CLD in our population. A larger study with good number of 
Non HCV CLD patients may overcome this limitation. 
5. Conclusion 
When it comes to its relationship with lipid metabolism, HCV is a remarkable virus. Its 
interaction with lipoproteins and its ability to induce massive steatosis are quite unique 
and idiosyncratic. Despite of causing hepatic steatosis, chronic HCV infection is asso-
ciated with a paradoxically favorable lipid profile, although its reason cannot be enligh-
tened precisely. There is a need for very well settled molecular and genetic studies to 
well understand HCV infection and lipid metabolism. 
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